Kineta 

$0.57
12
-$0.25-30.69% Wednesday 20:00

Statistics

Day High
0.83
Day Low
0.56
52W High
5.39
52W Low
0.33
Volume
480,683
Avg. Volume
504,100
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Dividends

0%Dividend Yield
Dec 22
$10.01
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

28MarExpected
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Q3 2024
Q4 2024
-0.89
-0.58
-0.27
0.04
Expected EPS
-0.24
Actual EPS
N/A

Financials

-259.08%Profit Margin
Unprofitable
2018
2019
2020
2021
2022
2023
5.44MRevenue
-14.1MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow KA. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. is a global healthcare company that develops medications and vaccines across various areas, including those that Kineta is involved in, making them direct competitors in the pharmaceutical and biotech space.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc. operates in the same biopharmaceutical field as Kineta, focusing on the discovery, development, and manufacture of healthcare products including medicines and vaccines.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol-Myers Squibb Company is a competitor due to its engagement in the discovery, development, and marketing of prescription pharmaceuticals in areas overlapping with Kineta's interests.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, Inc. competes with Kineta in the biopharmaceutical sector, particularly in the development and marketing of antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza.
AMGEN
AMGN
Mkt Cap160.66B
Amgen Inc. is a biotechnology company that competes with Kineta by focusing on areas such as oncology/hematology, cardiovascular disease, and inflammation.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie Inc. operates in the same pharmaceutical and biotechnology industry as Kineta, with a focus on immunology, oncology, and virology, among others.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals, Inc. is a biotechnology company that competes with Kineta in developing and commercializing medicines for the treatment of serious medical conditions.
Novartis
NVS
Mkt Cap237.61B
Novartis AG is a global healthcare company that competes with Kineta in researching, developing, manufacturing, and marketing a wide range of healthcare products.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson is a diverse healthcare company that competes with Kineta through its pharmaceutical segment, which develops and markets drugs in various therapeutic areas.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca PLC is a biopharmaceutical company that competes with Kineta in the development and commercialization of prescription medicines, including those for several diseases that Kineta targets.

About

Kineta, Inc., a clinical stage biotechnology company, develops immunotherapies for oncology, neuroscience, and biodefense. It serves private, government, and industry partners. The company has strategic partnerships with Pfizer, Genentech, Wellcome, and Samsung Biologics Co., Ltd. Kineta, Inc. was formerly known as Lecura, Inc. The company was incorporated in 2007 and is based in Seattle, Washington.
Show more...
CEO
Meenu Chhabra
Employees
11
Country
US

Listings

0 Comments

Share your thoughts

FAQ

What is Kineta stock price today?
The current price of KA is $0.57 USD — it has decreased by -30.69% in the past 24 hours. Watch Kineta stock price performance more closely on the chart.
What is Kineta stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Kineta stocks are traded under the ticker KA.
What is Kineta revenue for the last year?
Kineta revenue for the last year amounts to 5.44M USD.
What is Kineta net income for the last year?
KA net income for the last year is -14.1M USD.
Does Kineta pay dividends?
Yes, KA dividends are paid en. The last dividend per share was 10.01 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Kineta have?
As of April 01, 2026, the company has 11 employees.
In which sector is Kineta located?
Kineta operates in the Professional, Scientific, and Technical Services sector.
When did Kineta complete a stock split?
The last stock split for Kineta was on December 19, 2022 with a ratio of 1:7.
Where is Kineta headquartered?
Kineta is headquartered in Boston, US.